K4 Elite
K4 Elite
LL-37 is the only human cathelicidin-derived antimicrobial peptide, a 37-residue amphipathic host-defense peptide studied for its roles in innate immunity, microbial membrane disruption, and immunomodulation.
LL-37 is the mature, biologically active C-terminal fragment released from the human cathelicidin precursor protein hCAP-18 (encoded by the CAMP gene). It is named for its two N-terminal leucine residues and its length of 37 amino acids. It is the only cathelicidin-derived peptide identified in humans and is expressed by neutrophils, epithelial cells, and other tissues as part of the innate immune system.
Structurally, LL-37 is a cationic, amphipathic peptide that adopts an alpha-helical conformation in the presence of anionic lipids or physiological salt concentrations. This amphipathicity underlies much of the experimental interest in the peptide, as it allows interaction with negatively charged microbial membranes while researchers examine selectivity relative to host cells.
In the scientific literature LL-37 is investigated as a multifunctional host-defense molecule with reported activities spanning direct antimicrobial effects, modulation of immune-cell signaling, and interactions with wound-healing pathways in laboratory and animal models.
In model membrane systems, the cationic residues of LL-37 are reported to associate electrostatically with anionic phospholipids and lipopolysaccharide of microbial envelopes, after which the amphipathic helix is described as inserting into and permeabilizing the lipid bilayer. Researchers have proposed carpet-type and toroidal-pore models to describe the membrane-disruption behavior observed in vitro.
Beyond membrane effects, published studies describe LL-37 acting as a signaling ligand—reported interactions include the formyl peptide receptor-like 1 (FPRL1/FPR2) and modulation of Toll-like receptor responses, effects that investigators associate with chemotaxis of immune cells and altered cytokine release in cell-culture models.
In a study by Dürr, Sudheendra, and Ramamoorthy (2006, Biochimica et Biophysica Acta), the authors compiled and reviewed structural and biophysical experiments characterizing LL-37 conformation in different lipid environments, reporting salt- and lipid-dependent helix formation as a determinant of the peptide's membrane-active behavior in model systems.
Vandamme and colleagues (2012, Cellular Immunology) reviewed experimental datasets describing LL-37's immunomodulatory activities, summarizing cell-culture work in which the peptide altered chemotaxis and cytokine profiles of monocytes and other leukocytes.
Ramos and colleagues (2011) reviewed animal-model and in vitro wound-healing research in which cathelicidin expression or LL-37 application was associated with changes in re-epithelialization and angiogenesis markers; these reports describe experimental exposures in laboratory systems rather than any recommended human use.
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
References are being compiled for this entry.